Ansell SM, et al. - Researchers assessed efficacy and safety of nivolumab as well as genetic alterations of 9p24.1 in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who were ineligible for autologous hematopoietic cell transplantation (auto-HCT) or who had experienced failure with auto-HCT. The patients were administered nivolumab 3 mg/kg every 2 weeks. A total of 121 patients were treated. A median follow-up of 9 months in the auto-HCT–failed cohort and 6 months in the auto-HCT–ineligible cohort was performed, with median progression-free survival and overall survival being 1.9 and 12.2 months in the former and 1.4 and 5.8 months in the latter, respectively. The most common treatment-related grade 3 and 4 adverse events reported in 24% of patients included neutropenia (4%), thrombocytopenia (3%), and increased lipase (3%). Overall, a favorable safety profile but a low overall response rate was seen with nivolumab monotherapy in patients with DLBCL who were ineligible for auto-HCT or who experienced failure with auto-HCT. In DLBCL, infrequent genetic alterations of 9p24.1 were observed.